Please note - a separate email address is required for each medical professional attending the program.
PHA Preceptorship Program:
A Collaborative Approach for Clinicians on the Front Line
Georgetown University Hotel and Conference Center
Salon E/F, Main Level
3800 Reservoir Road NW
Washington, D.C.
9:00 - 9:30 AM
Registration
9:30 AM - Noon
Overview of Pulmonary Hypertension: Epidemiology and Pathophysiology
Mardi Gomberg-Maitland, MD, MSc, FACC, FCCP, FAHA
Diagnosis and Assessment of Pulmonary Hypertension
Christopher F. Barnett, MD, MPH
Selection of Appropriate Therapy
Stephen C. Mathai, MD, MHS, FCCP
Noon - 1:00 PM
Lunch
1:00 - 3:30 PM
Chronic Thromboembolic Pulmonary Hypertension
Oksana A. Shlobin, MD, FCCP
Pulmonary Arterial Hypertension Due to Connective Tissue Disease
Virginia D. Steen, MD
Case Presentations and Discussion
Tünay Kuru, MD, MHSA and Jason M. Elinoff, MD with Christopher F. Barnett, MD, MPH, Moderating
Preceptorship Faculty
Christopher F. Barnett, MD, MPH, Moderator
Director, Medical Cardiovascular Intensive Care Unit
Director, Pulmonary Hypertension Program
MedStar Heart and Vascular Institute
MedStar Washington Hospital Center
Mardi Gomberg-Maitland, MD, MSc, FACC, FCCP, FAHA
Professor of Medicine
Division of Cardiology
Medical Faculty Associates
George Washington University School of Medicine & Health Sciences
Medical Director, Pulmonary Hypertension Program
George Washington University Hospital
Tünay Kuru, MD, MHSA
Associate Professor of Medicine
Georgetown University School of Medicine
Director, Pulmonary Hypertension Program
Division of Pulmonary, Critical Care and Sleep Medicine
MedStar Georgetown University Hospital
Stephen C. Mathai, MD, MHS, FCCP
Associate Professor of Medicine
Pulmonary Hypertension Program
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University School of Medicine
Oksana A. Shlobin, MD, FCCP
Associate Professor of Clinical Medicine
Georgetown University School of Medicine and Virginia Commonwealth University
Medical Director, Pulmonary Hypertension Program
Inova Fairfax Hospital
Jason M. Elinoff, MD
Tenure-Track Investigator
Head, Pulmonary Vascular Biology Section
Co-Director, Translational Pulmonary Arterial Hypertension Program
Department of Critical Care Medicine
NIH Clinical Center
Virginia D. Steen, MD
Professor of Medicine
Georgetown University School of Medicine
Interim Chief, Division of Rheumatology, Clinical Immunology, and Allergy
MedStar Georgetown University Hospital
A complimentary lunch will be served.
To comply with the Sunshine Act, when a meal is provided, physicians will be asked for their National Provider Identification (NPI) and state license number at registration.
Target Audience
This activity has been designed for pulmonologists, cardiologists, rheumatologists, internists, and primary care physicians, as well as nurses, physician assistants, and other allied health professionals who help care for patients with pulmonary arterial hypertension (PAH).
Educational Objectives
The PHA Preceptorship Program is designed to improve competence, performance, and patient care practices by instructing front-line clinicians in the highest quality of case for patients with PAh by combining didactic discourse and highly interactive case-based discussion. At the conclusion of this program, participants should be able to:
- Define key pathophysiologic and epidemiologic components of PAh
- Accurately diagnose patients through comprehensive screening and early recognition of symptoms
- Evaluate the patient's condition and prescribe optimal long-term management, including knowing when and how to treat and when to consult with colleagues at an established PAH center
- Tailor comprehensive care for complex patient populations
|
Accreditation In support of improving patient care, this activity has been planned and implemented by Washington University School of Medicine in St. Louis, Continuing Medical Education and the Pulmonary Hypertension Association. Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
|
Credit Awarded for This Activity Washington University School of Medicine in St. Louis designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Disclosure Statement
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, that planners, faculty and other persons who may influence content of this CME activity disclose all relevant financial relationships with commercial interests in order for CME staff to identify and resolve any potential conflicts of interest prior to the educational activity. Faculty must also disclose any planned discussion of unlabled/unapproved uses of drugs or devices during their presentation. Detailed disclosures will be made in activity handout materials.
Preceptorship Medical Education Program Committee Members
Jean M. Elwing, MD, FCCP (Committee Chair), University of Cincinnati College of Medicine; Eric D. Austin, MD, MSCI, Vanderbilt University School of Medicine; Christopher F. Barnett, MD, MPH, MedStar Washington Hospital Center; Kelly Chin, MD, MSCS, University of Texas Southwestern Medical Center; Lorinda Chung, MD, MS, Stanford University School of Medicine; Richard A. Krasuski, MD, FACC, FAHA, FESC, Duke University School of Medicine; Gustavo A. Heresi, MD, MS, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; Tim Lahm, MD, Indiana University School of Medicine; Vallerie V. McLaughlin, MD, FACC, FAHA, FCCP (Advisor), Michigan Medicine
Washington University School of Medicine in St. Louis, CME Reviewers
Murali M. Chakinala, MD, FCCP — Content
Allyson R. Zazulia, MD — CME
This activity is supported by educational grants from:
Diamond Level Actelion Pharmaceuticals US, Inc.
|
Gold Level United Therapeutics Corporation
|